Work

ADVL1522: A phase 2 study of IMGN901 (lorvotuzumab mertansine; IND# 126953, NSC# 783609) in children with relapsed or refractory Wilms tumor, rhabdomyosarcoma, neuroblastoma, pleuropulmonary blastoma, malignant peripheral nerve sheath tumor (MPNST), and synovial sarcoma: A Children's Oncology Group study.

Year: 2017

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2017.35.15_suppl.10537

Authors: James I. Geller, Joseph Gerald Pressey, Malcolm A. Smith, Rachel A. Kudgus, Renee Schoon, Renee M. McGovern, Mariana Cajaiba, Joel M. Reid, David Hall, Donald A. Barkauskas, Jeffrey Dome, Elizabeth Fox, Brenda Weigel

Institutions: Cincinnati Children's Hospital Medical Center, National Cancer Institute, Mayo Clinic, Lurie Children's Hospital, Children's Oncology Group, University of Southern California, Children's National, University of Minnesota

Language: English

Topic: Sarcoma Diagnosis and Treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2766766587

Cites:

Cited by: 6

Related to: 10